iberdomide,idecabtagene vicleucel,bortezomib,lenalidomide
2seventy bio,bms
['ide-cel']
 i do commend the authors too- but to be honest this is disappointing, and ide-cel failed to correct the natural history of this aggressive disease. perhaps other products may do better for this population. #ash22
Cancer doctor at @huntsmancancer with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. No COI. Views own.